While there are other ways to guard against infection, like condoms, daily pills, vaginal rings and bi-monthly shots, experts ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

I'm sometimes asked how I started in AIDS organizing. Although it’s hard to pin when it happened, I will always remember ...

The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

The twice-yearly HIV prevention shot from Gilead Sciences has proven 100% effective in women and nearly as effective in men, ...

In February, it announced a collaboration with California’s Gilead Sciences to develop the cancer drug Trodelvy in a deal worth up to $210mn. Trodelvy is already approved to treat some cancers ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Right now, Gilead Sciences is sporting a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that GILD likely has seen a ...